Significantly higher. The operating profit and loss forecast for the fiscal year ending 24/3 has been revised upward from the previous deficit of 50 million yen to a surplus of 90 million yen (deficit of 0.25 million yen in previous fiscal year results). The performance of the drug discovery support business was improved by thoroughly reinforcing ready-to-work personnel and managing delivery dates. Also, in addition to the fact that price revisions based on the continuation of the depreciation trend of yen and the rise in product procurement costs have progressed in the investment/consulting business, it is expected that improvements have been seen in consumer purchasing motivation even at subsidiaries that operate e-commerce, contributing to the surplus transition.